Literature DB >> 6831826

Haloperidol kinetics after oral and intravenous doses.

F O Holley, J R Magliozzi, D R Stanski, L Lombrozo, L E Hollister.   

Abstract

Haloperidol kinetics were determined after oral and intravenous drug doses in 15 men. Mean elimination t1/2 for the subjects was 17.9 +/- 6.4 (SD) hr. After 0.125 mg/kg IV, mean distribution t1/2s in six subjects were 0.19 +/- 0.07 and 2 +/- 1 hr, and in 12 subjects mean clearance was 11.8 +/- 2.9 ml/kg/min and mean steady-state volume of distribution was 17.8 +/- 6.5 l/kg. After 0.50-mg/kg oral doses in eight subjects, mean lag time before drug absorption was 0.82 +/- 0.25 hr. Mean absorption t1/2 was 0.37 +/- 0.18 hr and mean distribution t1/2 was 0.96 +/- 0.20 hr. Bioavailability was 0.65 +/- 0.14 after oral doses. In 14 kinetic studies in nine subjects, data was analyzed by both model-dependent (open two- and three-compartment models using nonlinear regression) and model-independent (AUC and first moment curve) approaches. Results of the two were found to be in close agreement. The long elimination t1/2 of haloperidol is explained by the drug's extensive tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831826     DOI: 10.1038/clpt.1983.65

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  The effects of levodopa and haloperidol on flash and pattern ERGs and VEPs in normal humans.

Authors:  P Bartel; M Blom; E Robinson; C van der Meyden; D K Sommers; P Becker
Journal:  Doc Ophthalmol       Date:  1990-11       Impact factor: 2.379

2.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Pharmacokinetics of haloperidol in psychotic patients.

Authors:  Y F Cheng; L K Paalzow; U Bondesson; B Ekblom; K Eriksson; S O Eriksson; A Lindberg; L Lindström
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 7.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

8.  Human scalp hair as evidence of individual dosage history of haloperidol: a possible linkage of haloperidol excretion into hair with hair pigment.

Authors:  T Uematsu; R Sato; O Fujimori; M Nakashima
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

9.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.